Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial.

[1]  R. Holman,et al.  Baseline characteristics and temporal differences in Acarbose Cardiovascular Evaluation (ACE) trial participants , 2017, American heart journal.

[2]  J. Higaki,et al.  Does Treatment of Impaired Glucose Tolerance Improve Cardiovascular Outcomes in Patients with Previous Myocardial Infarction? , 2017, Cardiovascular Drugs and Therapy.

[3]  T. Sathyapalan,et al.  Impaired Glucose Tolerance or Newly Diagnosed Diabetes Mellitus Diagnosed during Admission Adversely Affects Prognosis after Myocardial Infarction: An Observational Study , 2015, PloS one.

[4]  R. Holman,et al.  The University of Oxford Diabetes Trials Unit. , 2015, European heart journal.

[5]  K. Malmberg,et al.  Sustained prognostic implications of newly detected glucose abnormalities in patients with acute myocardial infarction: Long-term follow-up of the Glucose Tolerance in Patients with Acute Myocardial Infarction cohort , 2015, Diabetes & vascular disease research.

[6]  M. Pfeffer,et al.  Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. , 2014, The lancet. Diabetes & endocrinology.

[7]  R. Holman,et al.  Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial. , 2014, American heart journal.

[8]  G. Roglić,et al.  Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study. , 2014, The lancet. Diabetes & endocrinology.

[9]  J. Tuomilehto,et al.  On the potential of acarbose to reduce cardiovascular disease , 2014, Cardiovascular Diabetology.

[10]  H. Ren,et al.  Effects of 24-week treatment with acarbose on glucagon-like peptide 1 in newly diagnosed type 2 diabetic patients: a preliminary report , 2013, Cardiovascular Diabetology.

[11]  J. Danesh,et al.  Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. , 2010, Lancet.

[12]  The Emerging Risk Factors Collaboration.  Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies , 2010, The Lancet.

[13]  M. Laakso,et al.  Effect of nateglinide on the incidence of diabetes and cardiovascular events. , 2010, The New England journal of medicine.

[14]  R. Califf,et al.  Determining the most appropriate components for a composite clinical trial outcome. , 2008, American heart journal.

[15]  R. Shannon,et al.  Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. , 2006, Journal of cardiac failure.

[16]  D. Hu,et al.  The relationship between coronary artery disease and abnormal glucose regulation in China: the China Heart Survey. , 2006, European heart journal.

[17]  Song-min Huang,et al.  Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. , 2006, Journal of the American Society of Nephrology : JASN.

[18]  P. Sawicki,et al.  Response to Chiasson et al.: Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data , 2004, Diabetologia.

[19]  M. Hanefeld,et al.  Acarbose Slows Progression of Intima-Media Thickness of the Carotid Arteries in Subjects With Impaired Glucose Tolerance , 2004, Stroke.

[20]  M. Hanefeld,et al.  Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. , 2004, European heart journal.

[21]  Markolf Hanefeld,et al.  Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. , 2003, JAMA.

[22]  M. Laakso,et al.  Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial , 2002, The Lancet.

[23]  A Sekikawa,et al.  Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. , 1999, Diabetes care.

[24]  R. Holman,et al.  A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44) , 1999, Diabetes care.

[25]  R. Bain,et al.  Predictors of Progression From Impaired Glucose Tolerance to NIDDM: An Analysis of Six Prospective Studies , 1997, Diabetes.

[26]  P. Bennett,et al.  The natural history of impaired glucose tolerance in the Pima Indians. , 1988, The New England journal of medicine.